Acclaimed comedian and actor Jon Lovitz is talking candidly for the first time about living with severe plaque psoriasis through a national disease awareness campaign called Are You Serious?™. Psoriasis is a chronic autoimmune condition which causes red, scaly plaques on the skin and affects nearly 7.5 million Americans, including Lovitz, who struggled with the condition for 10 years before getting its symptoms under control. Through his distinctive comedic style, Lovitz illustrates several of the everyday challenges faced by people with psoriasis in TV and radio public service announcements (PSAs), an entertaining song parody performed to Maroon 5’s famous hit, “This Love,” and an educational website – SeriousAboutPsoriasis.com.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/seriousaboutpsoriasis/47521/
Hundreds of CEOs from the healthcare, biotech and pharmaceutical industries plan to huddle next month with investment professionals to seek new business models to bridge healthcare’s gap between innovation and financial resources. They will be meeting at the 2nd Annual Global Leaders Healthcare Forum, in San Francisco on January 10, 2012. The forum is hosted by The Global Leaders, an exclusive business network of 2 million CEOs and other senior executives worldwide.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53879-the-global-leaders-healthcare-forum-san-francisco-2011
The Amgen Foundation today announced $2.5 million in new grants for the Amgen Biotech Experience, an innovative science education program, bringing the total committed to nearly $8 million since the program’s inception in 1990. The Amgen Biotech Experience provides a real-world biotech lab experience to middle and high schools in Amgen’s U.S. and United Kingdom (U.K.) communities and will engage more than 50,000 students this year. Education Development Center, Inc. (EDC), a global nonprofit organization that creates learning opportunities around the world, has also been named Program Office to oversee the program’s implementation and facilitate its continued development.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/59861-amgen-biotech-experience-lab-science-education-grants-for-students
AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange.
With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in more than 170 countries, AbbVie launches with an estimated $18 billion in annual revenues and a strong commitment to creating shareholder value through long-term growth potential and the continuation of the company’s history of shareholder dividends.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company
The Amgen Foundation announced today that it will invest more than $4 million to support and strengthen the Amgen Biotech Experience program across the United States, Puerto Rico, United Kingdom and Ireland. The Amgen Biotech Experience includes an engaging series of labs that effectively bring biotechnology into classrooms. This new commitment will also strengthen the program’s alignment with the United States’ Next Generation Science Standards, which are focused on engaging students in more authentic science learning experiences. With the support of Education Development Center, Inc. (EDC), the global nonprofit leading the Amgen Biotech Experience Program Office, the investment is expected to empower 1,000 teachers who will reach more than 150,000 new students with the labs over the next two years.
“We are very excited to extend our commitment to the Amgen Biotech Experience, a program that began 25 years ago, with the intent to ignite a deep passion for innovation and scientific discovery in students,” said Robert A. Bradway, chairman and chief executive officer of Amgen. “This program, which provides advanced biotech curriculum and professional-grade lab equipment at no cost to schools, has opened countless students’ eyes to the world of biotechnology, fueling potential long term advancements to both medicine and society.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7414055-amgen-biotech-experience-grant/
